Nippon Shinyaku, INNOVIVE Pharmaceuticals Conclude Licensing Agreement for NS-187, Drug Candidate for Chronic Myelogenous Leukemia.Tokyo, Japan, Jan 6, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Nippon Shinyaku announced on January 5 that it concluded a licensing agreement with INNOVIVE Pharmaceuticals of New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of on December 28, 2005. Under the agreement terms, INNOVIVE Pharmaceuticals will be licensed to exclusively develop and market NS-187, a drug candidate developed by Nippon Shinyaku, worldwide except in Japan. NS-187, which is a molecular targeted agent in the preclinical stage, is intended for the treatment of chronic myelogenous leukemia Chronic myelogenous leukemia (CML) Also called chronic myelocytic leukemia, malignant disorder that involves abnormal accumulation of white cells in the marrow and bloodstream. Mentioned in: Bone Marrow Transplantation (CML 1. CML - A query language. ["Towards a Knowledge Description Language", A. Borgida et al, in On Knowledge Base Management Systems, J. Mylopoulos et al eds, Springer 1986]. 2. CML - Concurrent ML. ). It is estimated that about 63,000 people in the world, of whom about 8,000 people live in Japan, have CML. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion